Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages

SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced multiple presentations highlighting the broad application of its Gene Circuit technologies in multiple modalities at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, CA.

“Our Gene Circuits are poised to potentially disrupt high-priority, unmet need diseases with smarter cell and gene therapies that can confer better activity, precision, and control,” said Timothy Lu, M.D., Ph.D., Chief Executive Officer and Co-Founder of Senti Bio. “Having such a strong presence at ASGCT validates the utility of our technology across multiple modalities, including NK cells, T cells, AAVs, iPSCs, and macrophages. We thank our partners for the productive collaborations and look forward to continued application of our platform to other disease indications.”

The presentations and posters can be accessed on the Scientific Presentations & Publications section of the Senti Bio website.

PRESENTATIONS HIGHLIGHTS

Oral Presentations
Engineering pharmacologically relevant, FDA-approved small-molecule-regulated gene circuits for therapeutic applications in the brain
Showcases gene circuit application in iPSC-derived cells in collaboration with BlueRock Therapeutics

Massively parallel and systematic engineering platform for highly compact, cell-type specific, and potent Smart Sensor promoters for precision retinal gene therapies
Showcases gene circuit application in AAV gene therapy in collaboration with Spark Therapeutics

Senti Bio’s Poster Presentations
High-throughput engineering of Logic Gated-gene circuits for precision CAR cell therapies

• Senti Bio has developed a robust platform for automated high throughput screening (HTS) of hundreds of CARs in parallel, in one self-contained, concurrent, end-to-end process.
• Automated HTS enables the programming of Logic Gated CAR cells to achieve high protection of healthy cells using the NOT GATE technology without compromising tumor-killing function.
• The data validates the Company’s NOT GATE technology in T cells as well as NK cells, thus enabling the ability to expand the Logic Gate technology into a wide range of cancers.